CellCura ASA (Oslo Axess: CELL), announces its results for the second quarter, 2014. A presentation will be held at 10 AM today at the Company's office at Vika Atrium, Munkedamsveien 45 A, 5th floor, Oslo.

The current cost cutting programme described in recent reports has now been completed with full effect as at the end of Q2. Future growth in the organisation will happen in conjunction with growth in each operating area and is contingent on available financial resources.

Short term financial constraints remain an issue and the company is currently relying on shareholder loans to meet its financial obligations. After the balance sheet date shareholders have extended further loans of NOK5.1m which are not reflected in the financials as at the end of Q2. This has provided the company with an adequate short-term liquidity. However, this does not constitute a viable long-term financing solution and Management and the Board of Directors will need to identify and put in place alternative financing solutions by the end of 2014.

Quarterly report attached.

Oslo, 29 August 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL)

www.cellcura.com

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

distributed by